Abstract
Non-alcoholic fatty liver disease (NAFLD) have a high prevalence in humans in the past two decades. Here, we elucidated the functions of miR-30a-3p in the development of NAFLD and identified its potential targets. HepG-2 cells and NAFLD patients’ blood samples were used in our study. Bioinformatics analysis as well as luciferase reporter assays were employed to distinguish peroxisome proliferator-activated receptor alpha (PPAR-α) as a target gene. Western blotting showed the expressions of lipid metabolic proteins and the target gene PPAR-α. Oil red O staining and triglyceride activity tested the fatty deposits after treatment with miR-30a-3p. miR-30a-3p was substantially up-regulated in NAFLD. Bioinformatics analyses showed that PPAR-α was a possible target of miR-30a-3p, linked with signaling pathways in NAFLD. PPAR-α as a novel target of miR-30a-3p, and suppression of its levels. The lipid metabolic-related proteins ACC, p-GSK-3β and FASN were up-regulated after transfecting with miR-30a-3p mimic, but the proteins CPT1, p-AMPK and UCP2 were down-regulated. miR-30a-3p inhibitor could diminish the protein manifestation of ACC, p-GSK-3β and FASN; and augment the protein manifestation of CPT1, p-AMPK and UCP2. On the contrary, overexpression of miR-30a-3p had adverse impacts on the performance of hepatocellular lipid accumulation and Triglyceride (TG) activity. Co-treatment with miR-30a-3p mimic and overexpression PPAR-α could revise the hepatic steatosis and the TG level induced by fat milk. Our findings suggest that miR-30a-3p/PPAR-α may be developed as a potential agent in NAFLD, which is enough to attenuate triglyceride accumulation and hepatic steatosis.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Betel D, Wilson M, Gabow A, Marks DS, Sander C (2008) The microRNA.org resource: targets and expression. Nucleic Acids Res 36:D149–D153. https://doi.org/10.1093/nar/gkm995
Conickx G et al (2017) microRNA profiling in lung tissue and bronchoalveolar lavage of cigarette smoke-exposed mice and in COPD patients: a translational approach. Sci Rep 7:12871. https://doi.org/10.1038/s41598-017-13265-8
David D et al (2017) Risk factors for non-alcoholic fatty liver disease are common in patients with non-B non-C hepatocellular carcinoma in India. Indian J Gastroenterol. https://doi.org/10.1007/s12664-017-0785-x
Detassis S, Grasso M, Del Vescovo V, Denti MA (2017) microRNAs make the call in cancer personalized medicine. Front Cell Dev Biol 5:86. https://doi.org/10.3389/fcell.2017.00086
Ding J, Li M, Wan X, Jin X, Chen S, Yu C, Li Y (2015) Effect of miR-34a in regulating steatosis by targeting PPARalpha expression in nonalcoholic fatty liver disease. Sci Rep 5:13729. https://doi.org/10.1038/srep13729
Du X, Cai C, Yao J, Zhou Y, Yu H, Shen W (2017) Histone modifications in FASN modulated by sterol regulatory element-binding protein 1c and carbohydrate responsive-element binding protein under insulin stimulation are related to NAFLD. Biochem Biophys Res Commun 483:409–417. https://doi.org/10.1016/j.bbrc.2016.12.129
Elhamamsy AR (2017) Role of DNA methylation in imprinting disorders: an updated review. J Assist Reprod Genet 34:549–562. https://doi.org/10.1007/s10815-017-0895-5
Firneisz G (2014) Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age? World J Gastroenterol 20:9072–9089. https://doi.org/10.3748/wjg.v20.i27.9072
Fu XT et al (2017) MicroRNA-30a suppresses autophagy-mediated anoikis resistance and metastasis in hepatocellular carcinoma. Cancer Lett. https://doi.org/10.1016/j.canlet.2017.10.012
Fukui N, Golabi P, Otgonsuren M, Mishra A, Venkatesan C, Younossi ZM (2017) Demographics, resource utilization, and outcomes of elderly patients with chronic liver disease receiving hospice care in the United States. Am J Gastroenterol. https://doi.org/10.1038/ajg.2017.290
Gross B, Pawlak M, Lefebvre P, Staels B (2017) PPARs in obesity-induced T2DM, dyslipidaemia and NAFLD. Nat Rev Endocrinol 13:36–49. https://doi.org/10.1038/nrendo.2016.135
Han L, Shen WJ, Bittner S, Kraemer FB, Azhar S (2017) PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part I: PPAR-alpha. Future Cardiol 13:259–278. https://doi.org/10.2217/fca-2016-0059
Hanin G et al (2017) miRNA-132 induces hepatic steatosis and hyperlipidaemia by synergistic multitarget suppression. Gut. https://doi.org/10.1136/gutjnl-2016-312869
He Z, Hu C, Jia W (2016) miRNAs in non-alcoholic fatty liver disease. Front Med 10:389–396. https://doi.org/10.1007/s11684-016-0468-5
Iacomino G, Siani A (2017) Role of microRNAs in obesity and obesity-related diseases. Genes Nutr 12:23. https://doi.org/10.1186/s12263-017-0577-z
Karatzas E, Bourdakou MM, Kolios G, Spyrou GM (2017) Drug repurposing in idiopathic pulmonary fibrosis filtered by a bioinformatics-derived composite score. Sci Rep 7:12569. https://doi.org/10.1038/s41598-017-12849-8
Korf H, van der Merwe S (2017) Adipose-derived exosomal MicroRNAs orchestrate gene regulation in the liver: Is this the missing link in nonalcoholic fatty liver disease? Hepatology. https://doi.org/10.1002/hep.29343
Kozomara A, Griffiths-Jones S (2011) miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res 39:D152–157. https://doi.org/10.1093/nar/gkq1027
Krek A et al (2005) Combinatorial microRNA target predictions. Nat Genet 37:495–500. https://doi.org/10.1038/ng1536
Lee JH et al (2018) Oxyresveratrol ameliorates nonalcoholic fatty liver disease by regulating hepatic lipogenesis and fatty acid oxidation through liver kinase B1 and AMP-activated protein kinase. Chem Biol Interact 289:68–74. https://doi.org/10.1016/j.cbi.2018.04.023
Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB (2003) Prediction of mammalian microRNA targets. Cell 115:787–798
Long MT et al (2018) Parental non-alcoholic fatty liver disease increases risk of non-alcoholic fatty liver disease in offspring. Liver Int. https://doi.org/10.1111/liv.13956
Maragkakis M et al (2011) DIANA-microT Web server upgrade supports Fly and Worm miRNA target prediction and bibliographic miRNA to disease association. Nucleic Acids Res 39:W145–148. https://doi.org/10.1093/nar/gkr294
Miranda KC et al (2006) A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell 126:1203–1217. https://doi.org/10.1016/j.cell.2006.07.031
Nie H et al (2017) MicroRNA-194 inhibition improves dietary-induced non-alcoholic fatty liver disease in mice through targeting on FXR. Biochim Biophys Acta. https://doi.org/10.1016/j.bbadis.2017.09.020
Ninomiya M et al (2016) The expression of miR-125b-5p is increased in the serum of patients with chronic hepatitis B infection and inhibits the detection of hepatitis B virus surface antigen. J Viral Hepat 23:330–339. https://doi.org/10.1111/jvh.12522
Otsuka M et al (2017) MicroRNAs and liver disease. J Hum Genet 62:75–80. https://doi.org/10.1038/jhg.2016.53
Peng Y et al (2018) The role of neutrophil to lymphocyte ratio for the assessment of liver fibrosis and cirrhosis: a systematic review. Expert Rev Gastroenterol Hepatol 12:503–513. https://doi.org/10.1080/17474124.2018.1463158
Qin G, Wang GZ, Guo DD, Bai RX, Wang M, Du SY (2018) Deletion of Smad4 reduces hepatic inflammation and fibrogenesis during nonalcoholic steatohepatitis progression. J Dig Dis 19:301–313. https://doi.org/10.1111/1751-2980.12599
Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R (2004) Fast and effective prediction of microRNA/target duplexes. RNA 10:1507–1517. https://doi.org/10.1261/rna.5248604
Rigano D, Sirignano C, Taglialatela-Scafati O (2017) The potential of natural products for targeting PPARalpha. Acta Pharm Sin B 7:427–438. https://doi.org/10.1016/j.apsb.2017.05.005
Shan K et al (2017) Circular noncoding RNA HIPK3 mediates retinal vascular dysfunction in diabetes mellitus. Circulation 136:1629–1642. https://doi.org/10.1161/CIRCULATIONAHA.117.029004
Shimagaki T et al (2017) MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection. Hepatol Res. https://doi.org/10.1111/hepr.12990
Singh AK, Pandey RK, Shaha C, Madhubala R (2016) MicroRNA expression profiling of Leishmania donovani-infected host cells uncovers the regulatory role of MIR30A-3p in host autophagy. Autophagy 12:1817–1831. https://doi.org/10.1080/15548627.2016.1203500
Spahis S, Delvin E, Borys JM, Levy E (2017) oxidative stress as a critical factor in nonalcoholic fatty liver disease pathogenesis. Antioxid Redox Signal 26:519–541. https://doi.org/10.1089/ars.2016.6776
Szabo G, Csak T (2016) Role of MicroRNAs in NAFLD/NASH. Dig Dis Sci 61:1314–1324. https://doi.org/10.1007/s10620-015-4002-4
Tsukamoto O et al (2014) Identification of endometrioid endometrial carcinoma-associated microRNAs in tissue and plasma. Gynecol Oncol 132:715–721. https://doi.org/10.1016/j.ygyno.2014.01.029
Utomo WK et al (2016) A MicroRNA panel in pancreatic cyst fluid for the risk stratification of pancreatic cysts in a prospective cohort. Mol Ther Nucleic Acids 5:e350. https://doi.org/10.1038/mtna.2016.61
Warren JS, Oka SI, Zablocki D, Sadoshima J (2017) Metabolic reprogramming via PPARalpha signaling in cardiac hypertrophy and failure: from metabolomics to epigenetics. Am J Physiol Heart Circ Physiol 313:H584–H596. https://doi.org/10.1152/ajpheart.00103.2017
Weiss TS et al (2017) Attenuated lipotoxicity and apoptosis is linked to exogenous and endogenous augmenter of liver regeneration by different pathways. PLoS ONE 12:e0184282. https://doi.org/10.1371/journal.pone.0184282
Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK (2017) Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther. https://doi.org/10.1111/apt.14342
Wu Q, Wang Q, Fu J, Ren R (2019) Polysaccharides derived from natural sources regulate triglyceride and cholesterol metabolism: a review of the mechanisms. Food Funct 10:2330–2339. https://doi.org/10.1039/c8fo02375a
Zhang S, Liu Q, Zhang Q, Liu L (2017) MicroRNA-30a-5p suppresses proliferation, invasion and tumor growth of hepatocellular cancer cells via targeting FOXA1. Oncol Lett 14:5018–5026. https://doi.org/10.3892/ol.2017.6745
Zhang M, Tang Y, Tang E, Lu W (2020) MicroRNA-103 represses hepatic de novo lipogenesis and alleviates NAFLD via targeting FASN and SCD1. Biochem Biophys Res Commun 524:716–722. https://doi.org/10.1016/j.bbrc.2020.01.143
Zheng F, Cai Y (2019) Concurrent exercise improves insulin resistance and nonalcoholic fatty liver disease by upregulating PPAR-gamma and genes involved in the beta-oxidation of fatty acids in ApoE-KO mice fed a high-fat diet. Lipids Health Dis 18:6. https://doi.org/10.1186/s12944-018-0933-z
Zhou M et al (2010) Rosiglitazone promotes fatty acyl CoA accumulation and excessive glycogen storage in livers of mice without adiponectin. J Hepatol 53:1108–1116. https://doi.org/10.1016/j.jhep.2010.05.034
Acknowledgements
This research was supported by Harbin Medical University Scientific Research Innovation Fund (No.2016JCZX55), Undergraduate Student Innovation Project (201810226069). We thank all members of the laboratory for insightful discussions and full help.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Supplementary file2 (TIF 463 kb)
Figure S1. The expression of PPAR-α after transfect with PPAR-α overexpressionvector.
Rights and permissions
About this article
Cite this article
Wang, DR., Wang, B., Yang, M. et al. Suppression of miR-30a-3p Attenuates Hepatic Steatosis in Non-alcoholic Fatty Liver Disease. Biochem Genet 58, 691–704 (2020). https://doi.org/10.1007/s10528-020-09971-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10528-020-09971-0